Neoadjuvant chemotherapy has become a standard treatment of advanced breast cancer. Various regimens have explored the addition of new agents to determine safety and efficacy. Our aim of this pilot study was to incorporate albumin-bound paclitaxel (ABP) with sequential anthracycline-based therapy as a neoadjuvant chemotherapy.Patients and methods
Twenty-four women with advanced breast cancer but without prior treatment and regardless of hormone receptor or HER2 status were enrolled. All patients were to receive albumin-bound paclitaxel (260 mg/m2) every 3 weeks for four cycles followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC100) every 3 weeks for 4 cycles. Trastuzumab was allowed in HER2-positive patients. Efficacy and safety was analyzed.Results
Twenty-three patients completed four cycles of ABP. 24 patients received at least two dose of FEC. Eight HER2+ women received trasuzumab only concomitant with ABP. The pCR in breast and axilla was 20.8% (5 of 24). For the HER2+ subset, the pCR was 62.5% (5 of 8). Both ABP and FEC were well tolerated. The most significant toxic effects were grade 2/3 neuropathy (52%) with ABP and grade 3/4 neutropenia (54%) with FEC.Conclusion
ABP given four cycles is well tolerated as neoadjuvant chemotherapy. ABP should be further evaluated in a randomized setting in a neoadjuvant trails.